Terra Innovatum Global N.V.

What they do

Terra Innovatum is developing SOLO, a compact 1 MWe micro-modular nuclear reactor designed to run continuously for 15 years without refueling, extendable to 45 years through core or reactor swaps, using commercially available low-enriched uranium (LEU). The design uses helium coolant, is intended to inhibit meltdown or explosion, and is built predominantly from off-the-shelf components; roughly 1,000 units could scale to 1 GWe. The company is a holding company with no direct operations and relies on its operating subsidiary, Terra Innovatum s.r.l. in Italy, and has not generated any revenue since inception. It is targeting commercial deployment of a first-of-a-kind reactor by 2028.

Revenue drivers

• SOLO reactor sales — The intended core business is selling or deploying 1 MWe SOLO micro-reactors, but the company has generated no revenue to date and does not expect revenue unless and until it commercializes its reactors.
• SOLO Test Reactor — A FOAK demonstrative prototype operated under a Class 104(c) non-power license, described as built primarily for testing, research, training and development rather than power production or revenue.
• Fleet-scale deployments — Company materials describe modularity from 1 MWe with one SOLO to 1 GWe with approximately 1,000 units, with redundancy designed into a 100-unit fleet; no such fleet sales have occurred.

Recent performance

For the three months ended June 30, 2026, the company reported a net loss of $18,044 thousand, versus $1,145 thousand for the three months ended June 30, 2025. For the six months ended June 30, 2026, the net loss was $25,150 thousand, versus $2,593 thousand in the prior-year period. Net cash used in operating activities was $8,778 thousand for the six months ended June 30, 2026, compared with $1,371 thousand a year earlier. Reported annual net income of $539.5 million for 2025 and diluted EPS of $9.74 contrast with a 2024 net loss of $34 thousand and an accumulated deficit of approximately $607.3 million as of December 31, 2025; the company attributes no revenue to any period. At June 30, 2026, total assets were $98.5 million, total liabilities $214.0 million, shareholder equity was negative $115.5 million, and cash and equivalents were $91.1 million.

Strategy

The stated priority is regulatory approval: the company submitted its regulatory engagement plan to the NRC, which is reviewing safety-related topics for SOLO, and management is targeting licensing and deployment of the FOAK reactor by 2028. It completed the reactor design sufficiently to support component fabrication and NRC licensing and validated key technological components, and it describes a supply chain strategy using off-the-shelf components and LEU, with HALEU as a longer-term option. The company intends to serve industrial, infrastructure, remote and off-grid markets one 1 MWe unit at a time. Management states it has limited financial resources and will likely need to raise additional capital to fund operations and development.

Risks

• No revenue and continuing losses — The company has never generated revenue, has an accumulated deficit of approximately $607.3 million as of December 31, 2025, and expects operating losses and negative cash flow to increase.
• Funding and solvency — Management states it has limited financial resources, that continued solvency depends on obtaining additional working capital, and that there is no assurance sufficient funding will be available.
• NRC licensing timing — Commercial rollout depends on NRC design, construction and operating approvals; the NRC is reviewing safety topics for SOLO and management says it cannot control the review process or guarantee timelines.
• Nasdaq listing-rule failures — The company disclosed delisting notices or listing-rule failures on April 17, 2026 and May 22, 2026, in addition to several director or officer changes and a change of accountants.

Outlook

Management targets commercial deployment of the first-of-a-kind SOLO reactor by 2028, following NRC licensing and component fabrication. It characterizes the near term as requiring continued capital raising while operating losses and negative cash flow increase. It also notes that 2026 interim losses widened versus the prior-year period and that previously reported results may not be indicative of future performance.